Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Behandling med aspirin efter præeklampsi: TAP-forsøg (TAP)

17. september 2026 opdateret af: Malamo Countouris

The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.

Studieoversigt

Detaljeret beskrivelse

This is a pilot randomized, single-center, double-blind placebo-control study of low dose aspirin in postpartum individuals with preeclampsia. Individuals will be randomized at the time of delivery 1:1 to 81mg of low-dose aspirin or identical appearing placebo daily for six months postpartum. Treatment and control groups will monitor home blood pressure throughout the study period and undergo two study visits. At each study visit, participants will undergo a blood draw, blood pressure measurement and assessment of endothelial function with microiontophoresis. Participant adherence will be monitored through pill counts, text message check-ins, patient diary and biochemical monitoring.

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

60

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Forenede Stater, 15213
        • Rekruttering
        • University of Pittsburgh Magee-Womens Hospital
        • Kontakt:
        • Ledende efterforsker:
          • Alisse K Hauspurg, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 55 år (Voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  • Postpartum individuals ≥18 years old
  • Preeclampsia diagnosis

Exclusion Criteria:

  • Fetal anomaly
  • Multiple gestation
  • Pre-pregnancy hypertension
  • Allergy or contraindication to low-dose aspirin
  • Pre-pregnancy diabetes

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Andet
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo Group

Similar appearing placebo pill daily for 6 months will be given to subjects.

The control group will receive similar appearing placebo daily for 6 months.

Eksperimentel: Intervention Group

Low-dose [81 mg] aspirin pill daily for 6 months will be given to subjects

The intervention group will receive low-dose [81 mg] aspirin pill daily for 6 months.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percent of participants eligible, enrolled and retained (feasibility)
Tidsramme: Baseline to approximately 6 months postpartum

To determine the feasibility of conducting a single-site randomized controlled trial of 6 months of postpartum low-dose aspirin vs. placebo in women with preeclampsia.

Baseline to approximately 6 months postpartum

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Study visit systolic BP
Tidsramme: 2 months postpartum

Mean study visit systolic BP

2 months postpartum
Study visit diastolic BP
Tidsramme: 2 months postpartum

Mean study visit diastolic BP

2 months postpartum
Study visit systolic BP
Tidsramme: 6 months postpartum

Mean study visit systolic BP

6 months postpartum
Study visit diastolic BP
Tidsramme: 6 months postpartum

Mean study visit diastolic BP

6 months postpartum
Study visit mean arterial pressure
Tidsramme: 2 months postpartum

Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3))

2 months postpartum
Study visit mean arterial pressure
Tidsramme: 6 months postpartum

Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3))

6 months postpartum
Anti-hypertensive medication use
Tidsramme: 2 months postpartum

Use of anti-hypertensive medication (percent of participants)

2 months postpartum
Anti-hypertensive medication use
Tidsramme: 6 months postpartum

Use of anti-hypertensive medication (percent of participants)

6 months postpartum
Therapeutic intensity score
Tidsramme: 2 months postpartum

Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome)

2 months postpartum
Therapeutic intensity score
Tidsramme: 6 months postpartum

Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome)

6 months postpartum
Mean home systolic blood pressure
Tidsramme: delivery through 6 months postpartum

Mean home systolic blood pressure

delivery through 6 months postpartum
Mean home diastolic blood pressure
Tidsramme: delivery through 6 months postpartum

Mean home diastolic blood pressure

delivery through 6 months postpartum
Mean home mean arterial pressure
Tidsramme: delivery through 6 months postpartum

Mean home mean arterial pressure

delivery through 6 months postpartum
Mean daytime systolic blood pressure
Tidsramme: 6 months postpartum

Mean daytime systolic blood pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean nocturnal systolic blood pressure
Tidsramme: 6 months postpartum

Mean nocturnal systolic blood pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean daytime diastolic blood pressure
Tidsramme: 6 months postpartum

Mean daytime diastolic blood pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean nocturnal diastolic blood pressure
Tidsramme: 6 months postpartum

Mean nocturnal diastolic blood pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean nocturnal mean arterial pressure
Tidsramme: 6 months postpartum

Mean nocturnal mean arterial pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean daytime mean arterial pressure
Tidsramme: 6 months postpartum

Mean daytime mean arterial pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean overall mean arterial pressure
Tidsramme: 6 months postpartum

Mean overall mean arterial pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean overall systolic blood pressure
Tidsramme: 6 months postpartum

Mean overall systolic blood pressure on ambulatory blood pressure monitoring

6 months postpartum
Mean overall diastolic blood pressure
Tidsramme: 6 months postpartum

Mean overall diastolic blood pressure on ambulatory blood pressure monitoring

6 months postpartum
Classification of hypertension
Tidsramme: 2 months postpartum

Stage 1, stage 2 hypertension (percent of participants with each stage)

2 months postpartum
Classification of hypertension
Tidsramme: 6 months postpartum

Stage 1, stage 2 hypertension (percent of participants with each stage)

6 months postpartum
Endothelial function EC50%
Tidsramme: 2 months postpartum

EC50% from microiontophoresis

2 months postpartum
Endothelial function EC50%
Tidsramme: 6 months postpartum

EC50% from microiontophoresis

6 months postpartum
Endothelial function Emax
Tidsramme: 2 months postpartum

Emax from microiontophoresis

2 months postpartum
Endothelial function Emax
Tidsramme: 6 months postpartum

Emax from microiontophoresis

6 months postpartum
Endothelial function change in Emax
Tidsramme: 2 to 6 months postpartum

Change in Emax between visits

2 to 6 months postpartum
Endothelial function change in EC50%
Tidsramme: 2 to 6 months postpartum

Change in EC50% between visits

2 to 6 months postpartum
Change in systolic blood pressure
Tidsramme: 2 to 6 months postpartum

Change in study visit mean systolic blood pressure between visits

2 to 6 months postpartum
Change in diastolic blood pressure
Tidsramme: 2 to 6 months postpartum

Change in study visit mean diastolic blood pressure between visits

2 to 6 months postpartum
Change in mean arterial pressure
Tidsramme: 2 to 6 months postpartum

Change in study visit mean arterial pressure between visits

2 to 6 months postpartum

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Alisse K Hauspurg, MD, UPMC Magee Women's Hospital

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

29. maj 2024

Primær færdiggørelse (Anslået)

1. januar 2027

Studieafslutning (Anslået)

1. oktober 2027

Datoer for studieregistrering

Først indsendt

15. februar 2024

Først indsendt, der opfyldte QC-kriterier

19. februar 2024

Først opslået (Faktiske)

28. februar 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

22. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

17. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

Deidentified data (including data dictionaries) will be shared at the discretion of the primary investigator. Data will include blood pressure, weight, demographics, physical activity, and pregnancy related information. Additional documents (such as the study protocol) will be made available.

IPD-delingstidsramme

Within a year after outcomes are published and no later than 3 years after the end of clinical activities.

IPD-delingsadgangskriterier

NHLBI data repository request process

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

produkt fremstillet i og eksporteret fra U.S.A.

Ja

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner